ALNY - alnylam.com Market Value

Alnylam Pharmaceuticals, Inc. - graphic logo of issuer ALNY

Alnylam Pharmaceuticals (ALNY) is seeing growing revenue stability driven by the sale of patent-protected therapies for orphan diseases, with a market capitalization of 22.10. The asset's market value trend confirms the successful implementation of the RNA interference method and the potential of new cardiology developments. The company's high standing as a pioneer in gene silencing ensures its impeccable status and the full confidence of the global medical community.

ALNY (Alnylam) Market Value history from 07/04/2022 to 11/16/2026

Financial and market metric breakdowns for Alnylam Pharmaceuticals (ALNY)

- market price and analyst price targets:
- market capitalization statistics:
Initial company analysis:Alnylam Corp ALNY
Original product of Alnylam Corp

Alnylam Pharmaceuticals (ALNY) maintains a monopoly position in the RNA interference segment for treating orphan diseases, ensuring high asset valuation driven by the uniqueness of its therapy and guaranteed insurance reimbursements. The product of the current share price and the number of outstanding shares quantifies market confidence in the business's stability, allowing the company's current market capitalization to track industry rotation phases and the risks of cyclical downturns.